drugset / Trial / NCT00263627

Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens

NCT00263627 ↗

Phase 3 Completed 253 enrolled Allergopharma GmbH & Co. KG
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this clinical trial is to show safety and efficacy of the allergoid preparation of birch pollen allergens in the treatment of birch allergic patients in a representative number of patients.

Timeline

Start
2005-06
Primary completion
2007-06
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Birch pollen allergoid Unknown 100 unknown Subcutaneous
Subject Birch pollen allergoid Unknown 1000 unknown Subcutaneous
Subject Birch pollen allergoid Unknown 10000 unknown Subcutaneous

Indications